Dhaval Patel

Company: Sana Biotechnology

Job title: Executive Vice President & Chief Scientific Officer

Seminars:

Enabling High Precision In Vivo CAR-T Therapy with Targeted Fusogens 1:45 pm

Comparing methods of cell specific in vivo CAR-T generation. Enabling high precision cell-specific gene editing with Sana’s Fusogen platform, which mediates cell entry via a mechanism that directly couples receptor recognition to cell entry, in contrast to endosomal escape delivery systems. Developing a T cell-specific Fusogen to enable in vivo CAR-T therapy, including in vivo…Read more

day: Day One